Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Phase 1b, multi-center, open label, sequential dose escalation trial assessing 3 dose cohorts
using a 3+3 design to evaluate safety and tolerability of Allocetra-OTS in adult patients
with moderate COVID-19. The sample size for this trial is anticipated to range from 9 to 18
patients.